April 04, 2013 06:26 PM Eastern Daylight Time
Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of
600,000 Shares of Common Stock
RUTHERFORD, N.J.--(BUSINESS WIRE)--Cancer Genetics, Inc., a diagnostics company focused on developing
genomic-based, oncology tests and services, today announced the pricing
of its initial public offering of 600,000 shares of its common stock at
a price to the public of $10.00 per share. The gross proceeds to Cancer
Genetics from the initial public offering are expected to be $6,000,000
(assuming no exercise of the over-allotment option), before underwriting
discounts and commissions and other offering expenses payable by Cancer
Genetics. Cancer Genetics has granted the representative of the
underwriters a 45-day option to purchase up to 90,000 additional shares
of common stock from Cancer Genetics to cover over-allotments, if any.
Shares of Cancer Genetics’ common stock are expected to be quoted on the
OTCQB Marketplace, operated by OTC Markets Group, under the symbol
“CGIX” beginning on April 5, 2013. Investors will be able to find Real
Time Level II quotes for “CGIX” on www.otcmarkets.com.
The offering is expected to close on April 10, 2013, subject to
customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the
offering.
Feltl and Company, Inc. is acting as co-manager for the offering.
This offering is being made only by means of a prospectus. Copies of the
prospectus relating to this offering may be obtained by contacting Aegis
Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor,
New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on April 4, 2013.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Cancer Genetics:
Cancer Genetics, Inc. is an early-stage diagnostics company focused on
developing and commercializing proprietary genomic tests and services to
improve and personalize the diagnosis, prognosis and response to
treatment (theranosis) of cancer. The proprietary tests being developed
by Cancer Genetics target cancers that are difficult to prognose and
predict treatment outcomes by using currently available mainstream
techniques. These cancers include hematological, urogenital and
HPV-associated cancers. Cancer Genetics recently has begun to provide
its proprietary tests and services along with a comprehensive range of
non-proprietary oncology-focused tests and laboratory services that it
has provided historically to oncologists and pathologists at hospitals,
cancer centers and physician offices. Cancer Genetics is currently
offering its tests and laboratory services in its 17,936 square foot
laboratory located in Rutherford, New Jersey, which has been accredited
under the Clinical Laboratory Improvement Amendments of 1988 to perform
high complexity testing.
Email 
Special home delivery offers!
